Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

1. Retinal Ganglion Cell Degeneration in Glaucoma: Systematic Review.Bioengineering (Basel, Switzerland) · 2026
   Review
2. Cannabinoids as Multitarget Drugs for the Treatment of Autoimmunity in Glaucoma.ACS pharmacology & translational science · 2025
   Review
3. AAV-mediated gene therapies for glaucoma and uveitis: are we there yet?Expert reviews in molecular medicine · 2024
   Review
4. Proteostasis in aging-associated ocular disease.Molecular aspects of medicine · 2022
   Review
5. Autophagy in glaucoma pathogenesis: Therapeutic potential and future perspectives.Frontiers in cell and developmental biology · 2022
   Review
6. A Fair Assessment of Evaluation Tools for the Murine Microbead Occlusion Model of Glaucoma.International journal of molecular sciences · 2021
   Article
7. What Is New in Glaucoma: From Treatment to Biological Perspectives.Journal of ophthalmology · 2021
   Review
8. Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.Annals of medicine · 2020
   Article
9. Retinal Tissue Bioengineering, Materials and Methods for the Treatment of Glaucoma.Tissue engineering and regenerative medicine · 2020
   Review
10. Effect of Mesenchymal Stem Cell-Derived Exosomes on Retinal Injury: A Review of Current Findings.Stem cells international · 2020
    Review
11. The Hub-and-Spoke Management of Glaucoma.Frontiers in neuroscience · 2020
    Review
12. Target-Derived Neurotrophic Factor Deprivation Puts Retinal Ganglion Cells on Death Row: Cold Hard Evidence and Caveats.International journal of molecular sciences · 2019
    Review
13. Experimental Models of Glaucoma: A Powerful Translational Tool for the Future Development of New Therapies for Glaucoma in Humans-A Review of the Literature.Medicina (Kaunas, Lithuania) · 2019
    Review
14. Targeted deletion of Cyp1b1 in pericytes results in attenuation of retinal neovascularization and trabecular meshwork dysgenesis.Trends in developmental biology · 2019
    Article
15. Vagal Nerve Stimulation Attenuates Ischemia-Reperfusion Induced Retina Dysfunction in Acute Ocular Hypertension.Frontiers in neuroscience · 2019
    Article
16. The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration.Frontiers in neuroscience · 2018
    Review
17. Reduced Annexin A1 Secretion by ABCA1 Causes Retinal Inflammation and Ganglion Cell Apoptosis in a Murine Glaucoma Model.Frontiers in cellular neuroscience · 2018
    Article
18. Caffeine Intake Effects on Intraocular Pressure in Healthy and Glaucomatous Populations: A Systematic Review and Meta-Analysis.Journal of current ophthalmology
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as